A detailed history of Perceptive Advisors LLC transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Perceptive Advisors LLC holds 892,208 shares of XENE stock, worth $34.8 Million. This represents 0.81% of its overall portfolio holdings.

Number of Shares
892,208
Previous 1,100,748 18.95%
Holding current value
$34.8 Million
Previous $50.7 Million 24.24%
% of portfolio
0.81%
Previous 1.24%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$42.66 - $50.04 $8.9 Million - $10.4 Million
-208,540 Reduced 18.95%
892,208 $38.4 Million
Q4 2023

Feb 14, 2024

BUY
$28.7 - $46.46 $13.9 Million - $22.5 Million
483,248 Added 78.26%
1,100,748 $50.7 Million
Q3 2023

Nov 14, 2023

SELL
$34.16 - $39.73 $20.7 Million - $24.1 Million
-605,877 Reduced 49.52%
617,500 $21.1 Million
Q2 2023

Aug 14, 2023

SELL
$34.84 - $43.54 $21.2 Million - $26.5 Million
-608,797 Reduced 33.23%
1,223,377 $47.1 Million
Q1 2023

May 15, 2023

SELL
$33.46 - $40.35 $2.98 Million - $3.6 Million
-89,099 Reduced 4.64%
1,832,174 $65.6 Million
Q4 2022

Feb 14, 2023

SELL
$33.06 - $39.43 $6.65 Million - $7.94 Million
-201,262 Reduced 9.48%
1,921,273 $75.8 Million
Q2 2022

Aug 15, 2022

SELL
$25.44 - $35.16 $7.35 Million - $10.2 Million
-288,912 Reduced 11.98%
2,122,535 $64.6 Million
Q4 2021

Feb 14, 2022

BUY
$15.6 - $35.4 $6.07 Million - $13.8 Million
389,396 Added 19.26%
2,411,447 $75.3 Million
Q3 2021

Nov 15, 2021

BUY
$14.86 - $19.45 $5.1 Million - $6.67 Million
343,078 Added 20.43%
2,022,051 $30.9 Million
Q2 2021

Aug 16, 2021

BUY
$16.81 - $20.0 $19.6 Million - $23.3 Million
1,163,931 Added 225.99%
1,678,973 $31.3 Million
Q1 2021

May 17, 2021

BUY
$13.65 - $21.31 $7.03 Million - $11 Million
515,042 New
515,042 $9.22 Million

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.43B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Perceptive Advisors LLC Portfolio

Follow Perceptive Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perceptive Advisors LLC with notifications on news.